Walking Fish Therapeutics develops engineered B cell medicines and a platform for protein factories and oncology applications. The company has expanded its pipeline to target oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. Since debuting in September 2021, its platform has demonstrated positive preclinical data across multiple indications. Walking Fish says recent innovations in B cell engineering and manufacturing enabled the pipeline expansion and new product opportunities. The company plans to use the new financing to accelerate platform development and further establish leadership in B cell therapeutics. Leadership includes Co-Founder and CEO Dr. Lewis “Rusty” Williams.

Total raised

$73M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2022